Leaders in the Program in Health Disparities Research (PHDR) and the Masonic Cancer Center, University of Minnesota recently received a $2,063,688 award from the National Cancer Institute/National Institutes of Health for their R25 project, “Minnesota Advancing Science, Enhancing Diversity: M-ASCEND.”
MINNEAPOLIS, MN - The FDA has granted Orphan Drug Designation to urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF, most commonly available as Pregnyl®) for the treatment of acute graft-versus-host-disease (GVHD). This designation will expedite the development and review of uhCG in treating acute GVHD, a potentially life-threatening complication following a hematopoietic cell transplant.
MINNEAPOLIS, MN- August 13, 2020 - A patient with COVID-19 and lung failure at the University of Minnesota is the first to be treated in the U.S. on a new FDA-approved clinical trial determining the safety and effectiveness of mesenchymal stem cells (MSCs).
MINNEAPOLIS, MN- August 6, 2020 - The first patient has received treatment in a new clinical trial that has opened at the University of Minnesota to test whether a novel cell therapy currently under clinical investigation as a treatment for acute myeloid leukemia (AML) and lymphoma can be effective as a treatment for COVID-19. The first-of-its-kind, engineered iPSC-derived natural killer (NK) cell product candidate, FT516, may play a role in diminishing viral replication of the novel coronavirus.
This summer the University of Minnesota Medical School Program in Health Disparities Research (PHDR) and the Masonic Cancer Center are hosting the 11th annual Health Disparities & Cancer Research Summer Internship program. This internship is designed to provide undergraduate students from Minnesota’s racial/ethnic minority and underrepresented communities an opportunity to gain hands-on research and clinical experiences pertaining to cancer, cancer disparities, and health disparities.
Kolawole S. Okuyemi, MD, MPH, and David Horne, PhD, will join the External Advisory Board of the Masonic Cancer Center, University of Minnesota.
The University of Minnesota Medical School’s Department of Radiation Oncology announces the appointment of Lindsey Sloan, MD, PhD, as an assistant professor starting July 31, 2020. Sloan, a radiobiologist, will also join the Masonic Cancer Center to advance her research with esteemed colleagues in the newly opened Masonic Cancer Center Discovery Labs.
The following Masonic Cancer Center members are the Principal Investigators on projects that were awarded National Cancer Institute (NCI) Research Grants in the latest grant cycle.